Thermo Fisher (TMO), a maker of scientific instruments, said Q4 EPS grew 15% to $1.36, topping estimates by 8 cents, led by demand from drugmakers and biotech companies. Revenue rose 6% to $3.26 bil, above forecasts for $3.14 bil. The company sees full-year EPS of $5.32-$5.46, the midpoint below views for $5.43, on revenue of $12.8 bil-$13 bil vs. estimates for $12.94 bil. Shares gained 2.5%.
As traders wait on the Federal Reserve, putting off any major decisions until they hear the latest word in FOMC …